Reslizumab in the management of poorly controlled asthma: the data so far
Diego Jose Maselli,1 Maria Ines Velez,1 Linda Rogers2 1Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Pulmonary, Critical Care, and Sleep Division, Mount Sinai—National Jewish Health Resp...
Main Authors: | Maselli DJ, Velez MI, Rogers L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-08-01
|
Series: | Journal of Asthma and Allergy |
Subjects: | |
Online Access: | https://www.dovepress.com/reslizumab-in-the-management--of-poorly-controlled-asthma-the-data-so--peer-reviewed-article-JAA |
Similar Items
-
Role of biologics in severe eosinophilic asthma – focus on reslizumab
by: Pelaia G, et al.
Published: (2016-07-01) -
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
by: Daniel P. Henriksen, et al.
Published: (2018-01-01) -
The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
by: H. Ibrahim, et al.
Published: (2019-12-01) -
Interleukin-5 in the Pathophysiology of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2019-12-01) -
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018-03-01)